Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies
Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration t...
Gespeichert in:
| Veröffentlicht in: | Chemical & pharmaceutical bulletin 2002, Vol.50(11), pp.1495-1498 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1498 |
|---|---|
| container_issue | 11 |
| container_start_page | 1495 |
| container_title | Chemical & pharmaceutical bulletin |
| container_volume | 50 |
| creator | Arno, Enose Appavoo Anand, Prithiviraj Bhaskar, Kesavan Ramachandran, Somasundaram Saravanan, Muniyandy Vinod, Radhakrishnan |
| description | Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration time, hardness, friability, thickness, weight variation, and in vitro drug release. The percentage of polymer, with respect to Metformin/Gliclazide, required to produce tablets with acceptable qualities was 9 to 13.45. The percentage of polymer below this range released the drug immediately and above this range produced granules not suitable for tablet formation. The quantity of Metformin/Gliclazide present in the tablets and the release medium were estimated by a validated HPLC method. The formulated tablets had acceptable physicochemical characters and released the drug over 6—8 h. The data obtained from in vitro release studies were fitted with various kinetic models and was found to follow Higuchi kinetics. |
| doi_str_mv | 10.1248/cpb.50.1495 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72668654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72668654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-783be06fce3d95efe0bb4dde45a4259c91bf64dd7de49a0c10f75f00c91f325d3</originalsourceid><addsrcrecordid>eNpFkEFv1DAQhS0EotvCiTvyBS6Q1o7teNMbXbYFqYAEhWs0scfFlTdZbEcqHPjtuGy0e7FH730zT3qEvODslNdyeWa2_akqs2zVI7LgQupK1bV4TBaMsbaqRSOOyHFKd4zVimnxlByVPd62XC_I3_VkI9z6TD-vBXtPLyChpZ8wuzFu_HB2FbwJ8MdbpOv7jIMt7lcMWDB6A33AnM7pZWGnANmPw1u6-gkRTMbo03-FwmCpH-gPn-O43_2WJ-sxPSNPHISEz-f_hHy_XN-sPlTXX64-rt5dV0ZqnSu9FD2yxhkUtlXokPW9tBalAlmr1rS8d00RdJFaYIYzp5VjrBhO1MqKE_J6d3cbx18TptxtfDIYAgw4TqnTddMsGyUL-GYHmjimFNF12-g3EH93nHUPdXel7k6VudRd6Jfz2anfoD2wc78FeDUDkAwEF2EwPh04KUomF4W72HF3KcMt7gGIufSP-1A-vw_pB7M03uEg_gHeAKEP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72668654</pqid></control><display><type>article</type><title>Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Arno, Enose Appavoo ; Anand, Prithiviraj ; Bhaskar, Kesavan ; Ramachandran, Somasundaram ; Saravanan, Muniyandy ; Vinod, Radhakrishnan</creator><creatorcontrib>Arno, Enose Appavoo ; Anand, Prithiviraj ; Bhaskar, Kesavan ; Ramachandran, Somasundaram ; Saravanan, Muniyandy ; Vinod, Radhakrishnan</creatorcontrib><description>Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration time, hardness, friability, thickness, weight variation, and in vitro drug release. The percentage of polymer, with respect to Metformin/Gliclazide, required to produce tablets with acceptable qualities was 9 to 13.45. The percentage of polymer below this range released the drug immediately and above this range produced granules not suitable for tablet formation. The quantity of Metformin/Gliclazide present in the tablets and the release medium were estimated by a validated HPLC method. The formulated tablets had acceptable physicochemical characters and released the drug over 6—8 h. The data obtained from in vitro release studies were fitted with various kinetic models and was found to follow Higuchi kinetics.</description><identifier>ISSN: 0009-2363</identifier><identifier>EISSN: 1347-5223</identifier><identifier>DOI: 10.1248/cpb.50.1495</identifier><identifier>PMID: 12419917</identifier><identifier>CODEN: CPBTAL</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>Biological and medical sciences ; Chemistry, Pharmaceutical ; Delayed-Action Preparations - pharmacokinetics ; Eudragit NE30D ; extended release tablets ; General pharmacology ; Gliclazide - pharmacokinetics ; HPLC ; Medical sciences ; Metformin - pharmacokinetics ; Metformin/Gliclazide ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polymethacrylic Acids - pharmacokinetics ; release kinetic ; Tablets</subject><ispartof>Chemical and Pharmaceutical Bulletin, 2002, Vol.50(11), pp.1495-1498</ispartof><rights>2002 The Pharmaceutical Society of Japan</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-783be06fce3d95efe0bb4dde45a4259c91bf64dd7de49a0c10f75f00c91f325d3</citedby><cites>FETCH-LOGICAL-c477t-783be06fce3d95efe0bb4dde45a4259c91bf64dd7de49a0c10f75f00c91f325d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14354313$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12419917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arno, Enose Appavoo</creatorcontrib><creatorcontrib>Anand, Prithiviraj</creatorcontrib><creatorcontrib>Bhaskar, Kesavan</creatorcontrib><creatorcontrib>Ramachandran, Somasundaram</creatorcontrib><creatorcontrib>Saravanan, Muniyandy</creatorcontrib><creatorcontrib>Vinod, Radhakrishnan</creatorcontrib><title>Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies</title><title>Chemical & pharmaceutical bulletin</title><addtitle>Chem. Pharm. Bull.</addtitle><description>Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration time, hardness, friability, thickness, weight variation, and in vitro drug release. The percentage of polymer, with respect to Metformin/Gliclazide, required to produce tablets with acceptable qualities was 9 to 13.45. The percentage of polymer below this range released the drug immediately and above this range produced granules not suitable for tablet formation. The quantity of Metformin/Gliclazide present in the tablets and the release medium were estimated by a validated HPLC method. The formulated tablets had acceptable physicochemical characters and released the drug over 6—8 h. The data obtained from in vitro release studies were fitted with various kinetic models and was found to follow Higuchi kinetics.</description><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>Delayed-Action Preparations - pharmacokinetics</subject><subject>Eudragit NE30D</subject><subject>extended release tablets</subject><subject>General pharmacology</subject><subject>Gliclazide - pharmacokinetics</subject><subject>HPLC</subject><subject>Medical sciences</subject><subject>Metformin - pharmacokinetics</subject><subject>Metformin/Gliclazide</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymethacrylic Acids - pharmacokinetics</subject><subject>release kinetic</subject><subject>Tablets</subject><issn>0009-2363</issn><issn>1347-5223</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFv1DAQhS0EotvCiTvyBS6Q1o7teNMbXbYFqYAEhWs0scfFlTdZbEcqHPjtuGy0e7FH730zT3qEvODslNdyeWa2_akqs2zVI7LgQupK1bV4TBaMsbaqRSOOyHFKd4zVimnxlByVPd62XC_I3_VkI9z6TD-vBXtPLyChpZ8wuzFu_HB2FbwJ8MdbpOv7jIMt7lcMWDB6A33AnM7pZWGnANmPw1u6-gkRTMbo03-FwmCpH-gPn-O43_2WJ-sxPSNPHISEz-f_hHy_XN-sPlTXX64-rt5dV0ZqnSu9FD2yxhkUtlXokPW9tBalAlmr1rS8d00RdJFaYIYzp5VjrBhO1MqKE_J6d3cbx18TptxtfDIYAgw4TqnTddMsGyUL-GYHmjimFNF12-g3EH93nHUPdXel7k6VudRd6Jfz2anfoD2wc78FeDUDkAwEF2EwPh04KUomF4W72HF3KcMt7gGIufSP-1A-vw_pB7M03uEg_gHeAKEP</recordid><startdate>20021101</startdate><enddate>20021101</enddate><creator>Arno, Enose Appavoo</creator><creator>Anand, Prithiviraj</creator><creator>Bhaskar, Kesavan</creator><creator>Ramachandran, Somasundaram</creator><creator>Saravanan, Muniyandy</creator><creator>Vinod, Radhakrishnan</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021101</creationdate><title>Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies</title><author>Arno, Enose Appavoo ; Anand, Prithiviraj ; Bhaskar, Kesavan ; Ramachandran, Somasundaram ; Saravanan, Muniyandy ; Vinod, Radhakrishnan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-783be06fce3d95efe0bb4dde45a4259c91bf64dd7de49a0c10f75f00c91f325d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>Delayed-Action Preparations - pharmacokinetics</topic><topic>Eudragit NE30D</topic><topic>extended release tablets</topic><topic>General pharmacology</topic><topic>Gliclazide - pharmacokinetics</topic><topic>HPLC</topic><topic>Medical sciences</topic><topic>Metformin - pharmacokinetics</topic><topic>Metformin/Gliclazide</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymethacrylic Acids - pharmacokinetics</topic><topic>release kinetic</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arno, Enose Appavoo</creatorcontrib><creatorcontrib>Anand, Prithiviraj</creatorcontrib><creatorcontrib>Bhaskar, Kesavan</creatorcontrib><creatorcontrib>Ramachandran, Somasundaram</creatorcontrib><creatorcontrib>Saravanan, Muniyandy</creatorcontrib><creatorcontrib>Vinod, Radhakrishnan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arno, Enose Appavoo</au><au>Anand, Prithiviraj</au><au>Bhaskar, Kesavan</au><au>Ramachandran, Somasundaram</au><au>Saravanan, Muniyandy</au><au>Vinod, Radhakrishnan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies</atitle><jtitle>Chemical & pharmaceutical bulletin</jtitle><addtitle>Chem. Pharm. Bull.</addtitle><date>2002-11-01</date><risdate>2002</risdate><volume>50</volume><issue>11</issue><spage>1495</spage><epage>1498</epage><pages>1495-1498</pages><issn>0009-2363</issn><eissn>1347-5223</eissn><coden>CPBTAL</coden><abstract>Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration time, hardness, friability, thickness, weight variation, and in vitro drug release. The percentage of polymer, with respect to Metformin/Gliclazide, required to produce tablets with acceptable qualities was 9 to 13.45. The percentage of polymer below this range released the drug immediately and above this range produced granules not suitable for tablet formation. The quantity of Metformin/Gliclazide present in the tablets and the release medium were estimated by a validated HPLC method. The formulated tablets had acceptable physicochemical characters and released the drug over 6—8 h. The data obtained from in vitro release studies were fitted with various kinetic models and was found to follow Higuchi kinetics.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>12419917</pmid><doi>10.1248/cpb.50.1495</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-2363 |
| ispartof | Chemical and Pharmaceutical Bulletin, 2002, Vol.50(11), pp.1495-1498 |
| issn | 0009-2363 1347-5223 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72668654 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Biological and medical sciences Chemistry, Pharmaceutical Delayed-Action Preparations - pharmacokinetics Eudragit NE30D extended release tablets General pharmacology Gliclazide - pharmacokinetics HPLC Medical sciences Metformin - pharmacokinetics Metformin/Gliclazide Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Polymethacrylic Acids - pharmacokinetics release kinetic Tablets |
| title | Eudragit NE30D Based Metformin/Gliclazide Extended Release Tablets: Formulation, Characterisation and in Vitro Release Studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T00%3A13%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eudragit%20NE30D%20Based%20Metformin/Gliclazide%20Extended%20Release%20Tablets:%20Formulation,%20Characterisation%20and%20in%20Vitro%20Release%20Studies&rft.jtitle=Chemical%20&%20pharmaceutical%20bulletin&rft.au=Arno,%20Enose%20Appavoo&rft.date=2002-11-01&rft.volume=50&rft.issue=11&rft.spage=1495&rft.epage=1498&rft.pages=1495-1498&rft.issn=0009-2363&rft.eissn=1347-5223&rft.coden=CPBTAL&rft_id=info:doi/10.1248/cpb.50.1495&rft_dat=%3Cproquest_cross%3E72668654%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72668654&rft_id=info:pmid/12419917&rfr_iscdi=true |